Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults.

Ermer J, Haffey MB, Richards C, Lasseter K, Roesch B, Purkayastha J, Corcoran M, Harlin B, Martin P.

Clin Drug Investig. 2013 Apr;33(4):243-54. doi: 10.1007/s40261-013-0073-1.

2.

Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.

Roesch B, Corcoran ME, Fetterolf J, Haffey M, Martin P, Preston P, Purkayastha J, Wang P, Ermer J.

Drugs R D. 2013 Jun;13(2):119-28. doi: 10.1007/s40268-013-0014-8.

4.

Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.

Haffey MB, Buckwalter M, Zhang P, Homolka R, Martin P, Lasseter KC, Ermer JC.

Postgrad Med. 2009 Sep;121(5):11-9. doi: 10.3810/pgm.2009.09.2048.

PMID:
19820270
5.

Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.

Ermer JC, Dennis K, Haffey MB, Doll WJ, Sandefer EP, Buckwalter M, Page RC, Diehl B, Martin PT.

Clin Drug Investig. 2011;31(6):357-70. doi: 10.2165/11588190-000000000-00000.

PMID:
21539403
6.

Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults.

Ermer J, Haffey MB, Richards C, Lasseter K, Adeyi B, Corcoran M, Stanton B, Martin P.

Neuropsychiatr Dis Treat. 2013;9:219-29. doi: 10.2147/NDT.S38377. Epub 2013 Feb 12.

9.

Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.

Martin P, Dirks B, Gertsik L, Walling D, Stevenson A, Corcoran M, Raychaudhuri A, Ermer J.

J Clin Psychopharmacol. 2014 Dec;34(6):682-9. doi: 10.1097/JCP.0000000000000205.

PMID:
25310201
10.

Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.

Krishnan SM, Pennick M, Stark JG.

Clin Drug Investig. 2008;28(12):745-55. doi: 10.2165/0044011-200828120-00002.

PMID:
18991468
12.

Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release.

Roesch B, Corcoran M, Haffey M, Stevenson A, Wang P, Purkayastha J, Martin P, Ermer J.

Drugs R D. 2013 Mar;13(1):53-61. doi: 10.1007/s40268-013-0009-5.

13.

Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.

J Am Acad Child Adolesc Psychiatry. 2011 Apr;50(4):395-405. doi: 10.1016/j.jaac.2011.01.007. Epub 2011 Mar 3.

PMID:
21421179
14.

Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults.

Ermer JC, Haffey MB, Doll WJ, Martin P, Sandefer EP, Dennis K, Corcoran M, Trespidi L, Page RC.

Drug Metab Dispos. 2012 Feb;40(2):290-7. doi: 10.1124/dmd.111.040691. Epub 2011 Oct 28.

15.
17.

Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.

Solans A, Izquierdo I, Donado E, Antonijoan R, Peña J, Nadal T, Carbó ML, Merlos M, Barbanoj M.

Clin Ther. 2008 Sep;30(9):1639-50. doi: 10.1016/j.clinthera.2008.09.002.

PMID:
18840369
18.

Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.

Wright CW, Aikman MS, Werts E, Seabolt J, Haeusler JM.

Clin Ther. 2009 Nov;31(11):2722-34. doi: 10.1016/j.clinthera.2009.11.025.

PMID:
20110014
19.

Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.

Madhoo M, Keefe RS, Roth RM, Sambunaris A, Wu J, Trivedi MH, Anderson CS, Lasser R.

Neuropsychopharmacology. 2014 May;39(6):1388-98. doi: 10.1038/npp.2013.334. Epub 2013 Dec 6.

20.

Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.

Ermer J, Homolka R, Martin P, Buckwalter M, Purkayastha J, Roesch B.

J Clin Pharmacol. 2010 Sep;50(9):1001-10. doi: 10.1177/0091270009357346. Epub 2010 Feb 19.

PMID:
20173084
Items per page

Supplemental Content

Write to the Help Desk